GlobeNewswire

Chinese visitors can now use Alipay in The Dubai Mall

Dela

Payment now accepted for popular luxury brands, world-class attractions including Dubai Aquarium & Underwater Zoo and At the Top, Burj Khalifa 

HANGZHOU, China and DUBAI, United Arab Emirates, April 25, 2018 (GLOBE NEWSWIRE) -- Alipay, the world's largest online and mobile payment platform operated by Ant Financial Services Group, and The Dubai Mall, the world's largest and most-visited retail and entertainment destination, located in the heart of the prestigious Downtown Dubai, today jointly announced that Chinese mainland visitors can now use Alipay to pay for a wide range of shopping, dining and must-see leisure attractions.

With the remarkable growth and importance of Chinese tourism to Dubai, The Dubai Mall is continuing to look at ways to accommodate their needs, which includes multilingual Guest Services staff and Chinese language Mall Guides.  
Chinese visitors can now look for stores across The Dubai Mall through Alipay's in-app Discover platform, and pay for their orders in RMB via Alipay at the cashiers.

Key destinations include The Souk, an elegantly designed precinct featuring jewellery shops, accessory outlets, traditional Arab clothing and handicraft stores; or The Village, which offers a rich collection of denim brands and brings an outdoor community feel with tree-lined walkways, cafés and restaurants; or the newly expanded Fashion Avenue, which provides a significant boost to Dubai's premium shopping options, with over 150 luxury shopping and dining experiences including flagships and new concepts.

In addition, Chinese visitors can use Alipay at all The Dubai Mall's popular entertainment attractions including Dubai Aquarium & Underwater Zoo, the newly opened VR ParkDubai Ice Rink and At the Top, Burj Khalifa, the world's highest observation deck with an outdoor terrace.

With a total internal floor area of 5.9 million sq ft, The Dubai Mall has 3.77 million sq ft of gross leasable space and over 1,300 retail outlets including two anchor department stores - Galeries Lafayette and Bloomingdale's - and over 200 global food and beverage outlets. The Dubai Mall offers an unparalleled retail mix combined with world-class dining, entertainment and leisure attractions.

The Dubai Mall, the world's largest shopping and entertainment destination, is part of Downtown Dubai, Emaar Properties' flagship mega-development.

Alipay currently has over 520 million active users in China. According to a report from Alipay and Nielsen, ease of payments is also a leading factor when it comes to key purchase decisions for Chinese tourists. 91% of Chinese tourists claimed they would show greater willingness to spend and shop if overseas merchants accepted Chinese mobile payments.

Statistics by The Department of Tourism and Commerce Marketing in Dubai show that over 764,000 Chinese tourists visited Dubai in the fiscal year of 2017, with a year-on-year growth of 41%, ranking China as the 5th largest source market of Dubai. Over 68,000 Chinese tourists visited Dubai this January*. 

Notes to editors
* Details of Chinese tourists visiting Dubai from  Visit Dubai
** Details of Chinese tourists' spending habits from a recent Alipay/Nielsen report (2018)

About Alipay 
Operated by Ant Financial Services Group, Alipay is the world's largest mobile and online payment platform. Launched in 2004, Alipay currently works with over 200 domestic financial institution partners. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Over 40 million brick-and-mortar merchants now accept Alipay across China. Alipay's in-store payment service covers over 40 countries and regions across the world, and tax reimbursement via Alipay is supported in 29 countries and regions. Alipay works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites. Alipay currently supports 27 currencies.

About The Dubai Mall:
Located in the heart of the prestigious Downtown Dubai is The Dubai Mall, the world's largest and most-visited retail and entertainment destination, which welcomed more than 80 million visitors annually. With a total internal floor area of 5.9 million sq ft, The Dubai Mall has 3.77 million sq ft of gross leasable space, over 1,300 retail outlets including two anchor department stores - Galeries Lafayette and Bloomingdale's - and over 200 food and beverage outlets.

The Dubai Mall acts as a gateway for visitors to Burj Khalifa, the global icon. Tickets to At the Top, Burj Khalifa SKY, the world's highest observation deck, are available exclusively to visitors of The Dubai Mall. For more information, visit www.thedubaimall.com or connect with @TheDubaiMall on  Instagram Twitter  &  Facebook

Media Enquiries
For more information on Alipay, please contact:
Xinyun Yang
International Communications
Ant Financial Services Group
Tel: +86 1381 6896 301
Email: xinyun.yang@antfin.com

For more information on The Dubai Mall, please contact:
Nivine William | Rania Moussly 
ASDA'A Burson-Marsteller
+9714 4507 600
nivine.william@bm.com | rania.moussly@bm.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ant Financial Services Group via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum